The Side of Implantable Central Vascular Catheters and Complications
Upper Extremity Deep Vein Thrombosis, Secondary
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Side of Implantable Central Vascular Catheters and Complications in Cancer Patients: A Randomization Observational Study|
- complication rates [ Time Frame: everey 4 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
left subclavian vein
CVC implanted in the left subclavian vein
right subclavian vein
CVC implanted in the right subclavian vein
Implantable central venous catheters (CVC) are crucial for cancer patients. They provide central venous access for chemotherapy and high-concentration nutrition support. However, several potential CVC-related complications may develop and severely interfere with the patients' cancer treatment and can be life-threatening in some occasions.
Thrombotic events occurred in around 20% of cancer patients with implantable CVCs. Such events included intraluminal thrombosis and catheter-related venous thrombosis. Catheter removal was usually necessary to resolve these conditions. Treatment delays are inevitable for these patients. Besides, these thrombotic complications were associated with catheter-related infection, which could be highly dangerous for cancer patients.
Risk factors associated with these thrombotic events included the hypercoagulable state of the patients, the cancer types, the catheter types, and the placement of the catheter tips in the superior vena cava. Some single-arm studies found that CVC inserted from the left subclavian veins led to more CVC-related thrombosis than those inserted from the right subclavian vein. However, for most right-handed patients, to place these implantable CVCs on the right side is inconvenient for daily life because vigorous exercise was then impossible. Besides, these single-arm studies could not well control the other potentially interfering factors, such as the operators, catheter location and cancer types.
Therefore, we plan a randomized observational study to explore whether the side of implantable CVCs was actually associated with the complication rates. Cancer patients who need implantable CVCs will be randomized to have the catheters implanted either in the left subclavian vein or the right subclavian. Patients who had breast cancer, mediastinal mass with the diameter > 6 cm, ECOG performance score >2, or those who were not able to receive a standing P-A view chest X-ray will be excluded. Patients who had other reasons that prevented the randomization will also be excluded. The catheter-related complications will be actively reported by the patients. We will also enforce the records of complications by chart reviews and regular telephone contacts.
With the study, we can demonstrate whether a left-sided CVC and a right-sided CVC are different in complication rates. The result should be very useful in clinical practice.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01525277
|Contact: Yu-Yun Shao, MD||886223123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Taipei City, Taiwan, 10002|
|Contact: Yu-Yun Shao, MD 886223123456 ext 67010 firstname.lastname@example.org|
|Principal Investigator: Yu-Yun Shao, MD|
|Sub-Investigator: Chih-Hung Hsu, MD, PhD|
|Sub-Investigator: Wen-Ying Lin, MD|
|Principal Investigator:||Yu-Yun Shao, MD||National Taiwan University Hospital|